Editorial
A single immediate instillation of chemotherapy for non-muscle invasive bladder cancer: in all patients?
Abstract
In order to determine the most appropriate schedule of adjuvant intravesical treatment after transurethral resection (TURBT) in patients with non-muscle invasive (Ta, T1, CIS) urothelial carcinoma of the bladder (NMIBC), the European Association of Urology (EAU) guidelines divide patients into three risk groups: low, intermediate and high risk (1).
